Select Page
nonconforming materials report

FDA 483 Observations from 2020

Every year, PathWise compiles information on the top FDA 483 observations from the previous year’s inspection observations. 2020 was a year like no other, with the Coronavirus halting FDA inspections for a time. The results for the year show a drastic reduction in inspections overall, however the trends remain consistent with previous years in what the top 483 observations are, and what organizations generally struggle with. See what the common violations are so you know where to start improvement projects in your quality systems!

Download your FREE White Paper!


* These fields are required.

FOLLOW PATHWISE!

CHECK OUT OTHER PATHWISE WHITE PAPERS!

Role-Based Training in Investigations and CAPA: Supporting Quality in Medical Device and Pharmaceutical Manufacturing

In the highly regulated environments of medical device and pharmaceutical manufacturing, ensuring...

White Paper: What’s the Right Number of CAPAs?

Spoiler alert- it’s not an exact number, and that number isn’t zero. The right number of CAPAs...

Key Performance Indicators for Life Science

Key Performance Indicators for Life Science The number of possible KPIs is endless. It all depends...

Free Download! Top 483 Observations from 2022

Top FDA 483 Warning Letter Observations from 2019 for Medical Device, Drugs, and Biologics Every...